Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

LBX Pharmacy Chain Joint Stock Company (603883.SS)

19.17
-0.16
(-0.83%)
As of 2:40:59 PM GMT+8. Market Open.
Loading Chart for 603883.SS
  • Previous Close 19.80
  • Open 19.15
  • Bid 19.18 x --
  • Ask 19.19 x --
  • Day's Range 19.08 - 19.89
  • 52 Week Range 11.90 - 28.38
  • Volume 32,553,533
  • Avg. Volume 26,280,922
  • Market Cap (intraday) 14.571B
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) 32.49
  • EPS (TTM) 0.59
  • Earnings Date --
  • Forward Dividend & Yield 0.33 (1.71%)
  • Ex-Dividend Date Oct 10, 2024
  • 1y Target Est --

LBX Pharmacy Chain Joint Stock Company operates pharmacy store chain in Mainland China. It operates through three segments: Retail business, Wholesale business, and Other. The company engages in the sale of drugs, and other health and beauty-related products through its marketing network. The company was formerly known as Laobaixing Pharmacy Chain Joint Stock Company. LBX Pharmacy Chain Joint Stock Company was founded in 2001 and is headquartered in Changsha, China.

www.lbxdrugs.com

40,132

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603883.SS

View More

Performance Overview: 603883.SS

Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603883.SS
17.10%
SSE Composite Index (000001.SS)
0.02%

1-Year Return

603883.SS
25.92%
SSE Composite Index (000001.SS)
7.16%

3-Year Return

603883.SS
4.54%
SSE Composite Index (000001.SS)
11.69%

5-Year Return

603883.SS
37.10%
SSE Composite Index (000001.SS)
15.79%

Compare To: 603883.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603883.SS

View More

Valuation Measures

As of 5/7/2025
  • Market Cap

    14.69B

  • Enterprise Value

    17.47B

  • Trailing P/E

    32.76

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.66

  • Price/Book (mrq)

    2.15

  • Enterprise Value/Revenue

    0.78

  • Enterprise Value/EBITDA

    17.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.02%

  • Return on Assets (ttm)

    3.13%

  • Return on Equity (ttm)

    8.05%

  • Revenue (ttm)

    22.25B

  • Net Income Avi to Common (ttm)

    448.44M

  • Diluted EPS (ttm)

    0.59

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.42B

  • Total Debt/Equity (mrq)

    70.12%

  • Levered Free Cash Flow (ttm)

    1.86B

Research Analysis: 603883.SS

View More

People Also Watch